Renapta B.V. develops systems to improve the condition of patients with severe kidney impairement.
The lead product of Renapta is a system for the selective clearance of certain uremic toxins from the blood of end stage renal disease patients undergoing renal dialysis.
Portfolio: MedSciences Seed Fund B.V.
Current product development stage: research.
